A perfect storm: Impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-2015 season

Clinical Infectious Diseases

Volumn 63, Issue 1, 2016, Pages 21-32

  Skowronski, Danuta M ^a,b   Chambers, Catharine ^a   Sabaiduc, Suzana ^a   De Serres, Gaston ^c,d,e   Winter, Anne Luise ^f   Dickinson, James A ^g   Krajden, Mel ^a,b   Gubbay, Jonathan B ^f,h   Drews, Steven J ^i,j   Martineau, Christine ^c   Eshaghi, Alireza ^f   Kwindt, Trijntje L ^a   Bastien, Nathalie ^k   Li, Yan ^k  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f PUBLIC HEALTH ONTARIO   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j Prov Laboratory of Northern Alberta   (Canada)

^k PUBLIC HEALTH AGENCY OF CANADA   (Canada)

more..

Author keywords

Antigenic drift; Genomics; Influenza vaccines; Sentinel surveillance; Vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE;

ADULT; ARTICLE; CANADA; CHILD; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC VARIATION; HUMAN; INFLUENZA A; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA B VIRUS; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS GENOME; ADOLESCENT; AGED; GENETICS; IMMUNOLOGY; INFANT; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MIDDLE AGED; PRESCHOOL CHILD; SENTINEL SURVEILLANCE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; GENOME, VIRAL; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SENTINEL SURVEILLANCE; YOUNG ADULT;

EID: 84981274535     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw176     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention. Influenza (flu). Past weekly surveillance reports. Available at: http://www.cdc.gov/flu/weekly/pastreports.htm. Accessed 4 April 2016.
2. Public Health Agency of Canada. Flu Watch. Weekly reports 2014-2015 season. Available at: http://www.phac- Aspc.gc.ca/fluwatch/14-15/index-eng.php. Accessed 4 April 2016.
3. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. Geneva: WHO, 2014. Available at: http://www.who.int/influenza/vaccines/virus/recommendations/2014-15-north/en/. Accessed 4 April 2016.
4. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. Geneva: WHO, 2015. Available at: http://www.who.int/influenza/vaccines/virus/recommendations/2015-16-north/en/. Accessed 4 April 2016.
5. Schanzer DL, Sevenhuysen C, Winchester B, Mersereau T. Estimating influenza deaths in Canada, 1992-2009. PLoS One 2013; 8:e80481.
6. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86.
7. Public Health Agency of Canada. Reported influenza hospitalizations and deaths in Canada: 2011-12 to 2015-16 (data to March 26, 2016). Available at: http://www.phac- Aspc.gc.ca/influenza/flu-stat-eng.php. Accessed 4 April 2016.
8. United Kingdom Office for National Statistics. Statistical Bulletin. Excess winter mortality in England and Wales 2014/15 (provisional) and 2013/14 (final). Available at: http://www.ons.gov.uk/ons/dcp171778-425192.pdf. Accessed 4 April 2016.
9. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: A systematic review. Expert Rev Vaccines 2014; 13:1571-91.
10. Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutations in the egg- Adapted H3N2 vaccine strain, not antigenic drift in circulating viruses. PLoS One 2014; 9:e92153.
11. Skowronski DM, Chambers C, Sabaiduc S, et al. Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccinevirus relatedness and effectiveness during the 2013-2014 influenza season. J Infect Dis 2015; 212:726-39.
12. Canadian Sentinel Practitioner Surveillance Network (SPSN). Vaccine effectiveness (VE) estimates against laboratory-confirmed, medically- Attended influenza, 2004-15 seasons. Available at: http://www.bccdc.ca/NR/rdonlyres/334939C9-3F64-4C22-8683-4067AC95CA9B/0/SPSN-VE-20042015-June-3-2015-dated.pdf. Accessed 4 April 2016.
13. Skowronski DM, Chambers C, Sabaiduc S, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill 2015; 20:pii:21022.
14. Gilca R, Skowronski DM, Douville-Fradet M, et al. Mid-season estimates of influenza vaccine effectiveness against A(H3N2) hospitalization in the elderly in Quebec, Canada, January 2015. PLoS One 2015; 10:e0132195.
15. McNeil SA, Andrew MK, Ye L, et al. Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. Euro Surveill 2015; 20:pii:21024.
16. Flannery B, Clippard J, Zimmerman RK, et al. Early estimates of seasonal influenza vaccine effectiveness-United States, January 2015.MMWR Morb Mortal Wkly Rep 2015; 64:10-5.
17. Pebody R, Warburton F, Andrews N, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill 2015; 20:pii:30013.
18. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 2011; 9:669-83.
19. Bush RM, Bender CA, Subbarao K, Cox NJ, Fitch WM. Predicting the evolution of human influenza A. Science 1999; 286:1921-5.
20. Ndifon W, Wingreen NS, Levin SA. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci USA 2009; 106:8701-6.
21. Popova L, Smith K, West AH, et al. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One 2012; 7:e41895.
22. Koel BF, Burke DF, Bestebroer TM, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 2013; 342:976-9.
23. Tate MD, Job ER, Deng Y-M, Gunalan V, Maurer-Stroh S, Reading PC. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses 2014; 6:1294-316.
24. An Y, McCullers JA, Alymova I, Parsons LM, Cipollo JF. Glycosylation analysis of engineered H3N2 influenza A virus hemagglutinins with sequentially added historically relevant glycosylation sites. J Proteome Res 2015; 14:3957-69.
25. Thompson MG, Naleway A, Fry AM, et al. Effects of repeated annual influenza vaccination among healthcare personnel on serum hemagglutination inhibition antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine 2016; 34:981-8.
26. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013; 56:1363-9.
27. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 2014; 59:1375-85.
28. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27.
29. Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-13 season: Assessments of prior vaccination and serologic susceptibility. J Infect Dis 2015; 211:1519-28.
30. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA 1999; 96:14001-6.
31. Price MN, Dehal PS, Arkin AP. FastTree 2- Approximately maximum-likelihood trees for large alignments. PLoS One 2010; 5:e9490.
32. Rambaut A. FigTree v1.4.0, a graphical viewer of phylogenetic trees. Edinburgh: University of Edinburgh. Available at: http://tree.bio.ed.ac.uk/software/figtree/. Accessed 4 April 2016.
33. Skowronski DM, Sabaiduc S, Chambers C, et al. Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses. Euro Surveill 2016; 21:pii:30112.
34. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 2003; 31:3381-5.
35. The PyMOL Molecular Graphics System, Version 1.6. Portland: Schrödinger, LLC.
36. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis 2015; 211:1529-40.
37. Cowling BJ, Feng S, Finelli L, Steffens A, Fowlkes A. Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010-13, United States. Vaccine 2016; 34:61-6.
38. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: A meta- Analysis of test negative design studies. Lancet Infect Dis 2016; doi:10.1016/S1473-3099(16)00129-8.
39. Flannery B, Clippard J. End-of-season influenza vaccine effectiveness estimates for the 2014-15 season: US influenza vaccine effectiveness (Flu VE) network. Advisory Committee on Immunization Practice presentation slides: June 2015. Available at: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-06/flu-02-flannery.pdf. Accessed 4 April 2016.
40. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Rep 2015; 12:1-6.
41. Appiah GD, Blanton L, D'Mello T, et al. Influenza activity - United States, 2014- 15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep 2015; 64:583-90.
42. Valenciano M, Kissling E, Reuss A, et al. Vaccine effectiveness in preventing laboratory- confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill 2016; 21:pii:30139.
43. Skowronski DM, De Serres G, Crowcroft NS, et al. Association between the 2008- 09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Med 2010; 7:e1000258.
44. Gilca R, Deceuninck G, De Serres G, et al. Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children. Pediatrics 2011; 128: E1084-91.
45. Crum-Cianflone NF, Blair PJ, Faix D, et al. Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza Avirus among United States military beneficiaries. Clin Infect Dis 2009; 49:1801-10.
46. Tsuchihashi Y, Sunagawa T, Yahata Y, et al. Association between seasonal influenza vaccination in 2008-2009 and pandemic influenza A(H1N1) 2009 infection among school students from Kobe, Japan, April-June 2009. Clin Infect Dis 2012; 54:381-3.
47. Cowling BJ, Ng S, Ma ES, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis 2010; 51:1370-9.
48. Skowronski DM, Hamelin ME, De Serres G, et al. Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk. PLoS One 2014; 9:e86555.
49. Gionet L. Flu vaccination rates in Canada. Health at a Glance. Statistics Canada catalogue no. 82-624-X. Available at: http://www.statcan.gc.ca/pub/82-624-x/2015001/article/14218-eng.htm. Accessed 4 April 2016.